167 related articles for article (PubMed ID: 22904129)
41. Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma.
Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Orsola I
Urology; 2005 Jan; 65(1):49-54. PubMed ID: 15667862
[TBL] [Abstract][Full Text] [Related]
42. Double cocktail immunostains with high molecular weight cytokeratin and GATA-3: useful stain to discriminate in situ involvement of prostatic ducts or acini from stromal invasion by urothelial carcinoma in the prostate.
Lee J; Yoo Y; Park S; Cho MS; Sung SH; Ro JY
J Pathol Transl Med; 2020 Mar; 54(2):146-153. PubMed ID: 32028755
[TBL] [Abstract][Full Text] [Related]
43. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
44. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
[TBL] [Abstract][Full Text] [Related]
45. The clinical use of a P63/cytokeratin7/18/cytokeratin5/14 antibody cocktail in diagnostic breast pathology.
Reisenbichler ES; Ross JR; Hameed O
Ann Diagn Pathol; 2014 Dec; 18(6):313-8. PubMed ID: 25224390
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of biomarkers in breast and prostate cancer.
Grizzle WE; Myers RB; Arnold MM; Srivastava S
J Cell Biochem Suppl; 1994; 19():259-66. PubMed ID: 7823598
[TBL] [Abstract][Full Text] [Related]
47. Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer.
Mazzucchelli R; Barbisan F; Santinelli A; Scarpelli M; Galosi AB; Lopez-Beltran A; Cheng L; Kirkali Z; Montironi R
Urology; 2009 Aug; 74(2):385-90. PubMed ID: 19501882
[TBL] [Abstract][Full Text] [Related]
48. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.
Yin H; Leong AS
Am J Clin Pathol; 2004 May; 121(5):679-87. PubMed ID: 15151208
[TBL] [Abstract][Full Text] [Related]
49. Urothelial carcinoma in the prostatic urethra and prostate: current controversies.
Liedberg F; Chebil G; Månsson W
Expert Rev Anticancer Ther; 2007 Mar; 7(3):383-90. PubMed ID: 17338657
[TBL] [Abstract][Full Text] [Related]
50. [A useful panel in proliferative urothelial lesions: an analysis of cytokeratin 20, p53, CD44 and Ki-67 antigens].
Russo S; Botti G; Vinaccia P; Iaccarino C; Maioli S; Del Prete D; Maiello FM
Pathologica; 2007 Apr; 99(2):46-9. PubMed ID: 17633807
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
52. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
53. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion.
Esrig D; Freeman JA; Elmajian DA; Stein JP; Chen SC; Groshen S; Simoneau A; Skinner EC; Lieskovsky G; Boyd SD; Cote RJ; Skinner DG
J Urol; 1996 Sep; 156(3):1071-6. PubMed ID: 8709310
[TBL] [Abstract][Full Text] [Related]
54. Primary carcinoma of renal calyx.
Williams PA; Mai KT
Pathol Res Pract; 2013 Oct; 209(10):654-61. PubMed ID: 23999038
[TBL] [Abstract][Full Text] [Related]
55. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas.
Bayrak R; Yenidünya S; Haltas H
Pathol Res Pract; 2011 Mar; 207(3):156-60. PubMed ID: 21282015
[TBL] [Abstract][Full Text] [Related]
56. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
[TBL] [Abstract][Full Text] [Related]
57. Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.
Trpkov K; Bartczak-McKay J; Yilmaz A
Am J Clin Pathol; 2009 Aug; 132(2):211-20; quiz 307. PubMed ID: 19605815
[TBL] [Abstract][Full Text] [Related]
58. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
[TBL] [Abstract][Full Text] [Related]
59. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
60. [A case report of carcinoma in situ of the bladder invading the prostate following BCG therapy].
Matsushita M; Okada T; Koh Y; Wang C; Ujike T; Nin M; Tsujihata M
Hinyokika Kiyo; 2014 Jun; 60(6):283-6. PubMed ID: 25001644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
